Fig. 5.
Inhibition of VEGF-triggered ERK activation by blockade of VEGF and MEK-1.
MM.1S and patient MM cells pretreated as described in Figure 4A were either stimulated with 100 ng/mL VEGF165 alone (panel A) or treated for 30 minutes with 30 μg/mL anti–human VEGF antibody (anti-VEGF) (panel B) or for 1 hour with 50 μM PD89059 (panel C) prior to VEGF stimulation. Cells were solubilized, and whole cell lysates (40 μg) were analyzed by Western blotting with antisera against dually phosphorylated MAPK (ERK-1, ERK-2). Equal loading was confirmed by immunoblotting the membranes with antisera against ERK-2.
